Hudson Bay Capital Management LP Reduces Stock Position in United Therapeutics Corporation $UTHR

Key Points

• Hudson Bay Capital Management LP cut its stake in United Therapeutics by 67.1% in Q3 to 21,524 shares (~$9.02M), while institutional ownership remains very high at about 94% with several large funds (Darwin Global, Norges Bank, Invesco, AQR, Balyasny) adding or increasing positions.
• Analysts are largely positive—nine Buys versus three Holds—with an average price target of $548.09 and notable hikes from firms like UBS and HC Wainwright, supported by a recent EPS beat ($7.70 vs. $6.78 consensus) despite a modest revenue miss.
• Insider selling has been significant: insiders disposed of 347,320 shares (~$171.4M) over the past 90 days, including recent sales by senior executives and a mid‑March sale by CEO Martine Rothblatt, which may exert downward pressure on the stock.

Hudson Bay Capital Management LP cut its holdings in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 67.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 21,524 shares of the biotechnology company's stock after selling 43,823 shares during the period. Hudson Bay Capital Management LP's holdings in United Therapeutics were worth $9,023,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of UTHR. Darwin Global Management Ltd. bought a new stake in shares of United Therapeutics during the 3rd quarter valued at $317,617,000. Norges Bank bought a new position in United Therapeutics in the 2nd quarter worth about $136,453,000. Invesco Ltd. boosted its stake in United Therapeutics by 90.2% in the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company's stock worth $254,219,000 after purchasing an additional 419,588 shares during the period. AQR Capital Management LLC grew its holdings in United Therapeutics by 40.1% during the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company's stock valued at $362,876,000 after buying an additional 364,713 shares in the last quarter. Finally, Balyasny Asset Management L.P. grew its holdings in United Therapeutics by 863.9% during the 2nd quarter. Balyasny Asset Management L.P. now owns 152,727 shares of the biotechnology company's stock valued at $43,886,000 after buying an additional 136,883 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on UTHR shares. Weiss Ratings reissued a "buy (b)" rating on shares of United Therapeutics in a report on Monday, December 29th. Jefferies Financial Group reaffirmed a "buy" rating on shares of United Therapeutics in a research note on Monday, March 2nd. UBS Group upped their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a "buy" rating in a report on Thursday, March 5th. HC Wainwright raised their price target on shares of United Therapeutics from $525.00 to $600.00 and gave the company a "buy" rating in a report on Thursday, February 26th. Finally, Bank of America reissued a "neutral" rating on shares of United Therapeutics in a report on Wednesday, February 25th. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, United Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $548.09.

Insider Transactions at United Therapeutics

In other news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $502.79, for a total value of $11,312,775.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction dated Wednesday, December 24th. The shares were sold at an average price of $513.18, for a total value of $5,644,980.00. Following the completion of the sale, the executive vice president directly owned 36,781 shares of the company's stock, valued at approximately $18,875,273.58. This trade represents a 23.02% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 347,320 shares of company stock worth $171,380,893 over the last ninety days. Insiders own 10.30% of the company's stock.

United Therapeutics Price Performance

Shares of UTHR opened at $527.00 on Friday. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $548.12. The stock has a 50 day simple moving average of $489.57 and a two-hundred day simple moving average of $466.41. The firm has a market cap of $23.10 billion, a P/E ratio of 18.89, a P/E/G ratio of 1.91 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping the consensus estimate of $6.78 by $0.92. The firm had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business's revenue was up 7.4% compared to the same quarter last year. During the same period last year, the firm posted $6.19 earnings per share. On average, equities analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Analysts have largely raised targets and maintained buy/outperform views, supporting valuation — multiple firms (UBS, RBC, TD Cowen, Cantor Fitzgerald, Jefferies) recently lifted targets or reiterated buy ratings, keeping the consensus at a moderate buy. MarketBeat UTHR coverage
• Positive Sentiment: Solid recent quarterly results: UTHR reported an EPS beat (reported $7.70 vs. $6.78 consensus) with healthy margins, which supports earnings momentum despite a modest revenue miss. Earnings summary
• Neutral Sentiment: Sector comparison pieces (e.g., CPRX vs UTHR) are circulating; these may attract relative‑value buyers but are not company‑specific catalysts. Zacks comparison
• Neutral Sentiment: Institutional ownership remains very high (~94%) with some recent modest position changes by funds — this can mute volatility from retail flows but also concentrates sell pressure when insiders sell. MarketBeat institutional note
• Negative Sentiment: CEO Martine Rothblatt sold a large block in mid‑March — roughly 9,500 shares at about $533–$538/share (≈$5.1M), with filings showing a substantial reduction in her direct stake; such headline insider selling typically pressures the stock. SEC filing
• Negative Sentiment: EVP Paul A. Mahon sold 8,300 shares at an average ~$529.95 (≈$4.4M) on March 19, further adding to sell‑side pressure from insiders. SEC filing

United Therapeutics Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.